Carl Icahn happy with Board Representation at Amylin Pharma
|February 10th, 2010||
|Contributed by: Hedge Fund Solutions LLC|
|Shareholder activist investor Carl Icahn stated on January 25th that he will not seek additional representation on Amylin Pharmaceuticals, Inc.’s (NASDAQ: AMLN) board because enough board members approve of re-nominating two candidates that were appointed last year after a proxy contest with Mr. Icahn’s Icahn Associates and Eastbourne Capital Management LLC. Icahn’s hedge funds currently hold 12,971,328 shares of Amylin or 9.43% of shares outstanding.|
Hedge Fund Solutions previously covered AMLN in numerous Catalyst Research Reports, highlighting Icahn’s and Eastbourne Capital’s (12.5%) successful attempt to replace two board members up for election in 2009.
For Detailed Investor Profiles on these Investors, click below: